Tag: #pembrolizumab

Interim phase 3: Sacituzumab tirumotecan plus pembrolizumab improves PFS in PD-L1–positive advanced NSCLC

Interim phase 3 data: adding sacituzumab tirumotecan to pembrolizumab improved progression-free survival versus pembrolizumab alone in PD‑L1+ advanced NSCLC; OS immature, toxicity higher.

$MRK, #lungcancer, #pembrolizumab, #sacituzumabtirumotecan, #clinicaltrials

NHS England rolls out 60-second pembrolizumab injection to cut treatment chair time

NHS England is introducing a subcutaneous form of pembrolizumab (Keytruda) that can be given in about a minute, reducing clinic time for roughly 14,000 patients.

#nhs, #pembrolizumab, #cancer, #immunotherapy